Chimerix Inc (NASDAQ:CMRX)’s stock price dropped 13.6% during mid-day trading on Tuesday . The company traded as low as $2.01 and last traded at $2.03, approximately 602,327 shares were traded during trading. An increase of 39% from the average daily volume of 432,653 shares. The stock had previously closed at $2.35.
CMRX has been the topic of a number of research analyst reports. HC Wainwright boosted their price target on Chimerix from $5.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, August 1st. ValuEngine upgraded Chimerix from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research upgraded Chimerix from a “sell” rating to a “hold” rating in a report on Monday, September 23rd. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $4.00.
The company has a market cap of $144.60 million, a PE ratio of -1.42 and a beta of 1.35. The business has a fifty day moving average of $2.31 and a 200-day moving average of $2.90.
A number of large investors have recently made changes to their positions in CMRX. SG Americas Securities LLC increased its holdings in Chimerix by 105.4% during the 1st quarter. SG Americas Securities LLC now owns 20,590 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 10,567 shares during the period. Quantitative Systematic Strategies LLC purchased a new position in shares of Chimerix during the 2nd quarter worth approximately $67,000. Susquehanna International Group LLP purchased a new position in shares of Chimerix during the 2nd quarter worth approximately $92,000. Prudential Financial Inc. purchased a new position in shares of Chimerix during the 2nd quarter worth approximately $104,000. Finally, Marshall Wace LLP purchased a new position in shares of Chimerix during the 1st quarter worth approximately $166,000. Institutional investors own 63.43% of the company’s stock.
About Chimerix (NASDAQ:CMRX)
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Featured Story: Understanding Analyst Ratings
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.